- Home
- SONO vs CGON Comparison
SONO vs CGON Comparison
Compare SONO & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- CGON
- Stock Information
- Founded
- SONO 2002
- CGON 2010
- Country
- SONO United States
- CGON United States
- Employees
- SONO N/A
- CGON N/A
- Industry
- SONO Consumer Electronics/Video Chains
- CGON
- Sector
- SONO Consumer Discretionary
- CGON
- Exchange
- SONO Nasdaq
- CGON NYSE
- Market Cap
- SONO 1.1B
- CGON 1.3B
- IPO Year
- SONO 2018
- CGON 2024
- Fundamental
- Price
- SONO $10.04
- CGON $26.91
- Analyst Decision
- SONO Buy
- CGON Strong Buy
- Analyst Count
- SONO 3
- CGON 10
- Target Price
- SONO $13.00
- CGON $64.00
- AVG Volume (30 Days)
- SONO 1.7M
- CGON 974.4K
- Earning Date
- SONO 05-07-2025
- CGON 05-13-2025
- Dividend Yield
- SONO N/A
- CGON N/A
- EPS Growth
- SONO N/A
- CGON N/A
- EPS
- SONO N/A
- CGON N/A
- Revenue
- SONO $1,463,138,000.00
- CGON $662,000.00
- Revenue This Year
- SONO N/A
- CGON N/A
- Revenue Next Year
- SONO $3.27
- CGON $12,387.03
- P/E Ratio
- SONO N/A
- CGON N/A
- Revenue Growth
- SONO N/A
- CGON 224.51
- 52 Week Low
- SONO $7.63
- CGON $14.80
- 52 Week High
- SONO $16.30
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- SONO 48.87
- CGON 58.13
- Support Level
- SONO $9.84
- CGON $26.25
- Resistance Level
- SONO $10.38
- CGON $27.15
- Average True Range (ATR)
- SONO 0.33
- CGON 1.28
- MACD
- SONO -0.06
- CGON 0.06
- Stochastic Oscillator
- SONO 35.78
- CGON 70.13
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.